Research/art/teacher profile of a person
Name and surname:
doc. RNDr. Andrej Boháč, CSc.
Document type:
Research/art/teacher profile of a person
The name of the university:
Comenius University Bratislava
The seat of the university:
Šafárikovo námestie 6, 818 06 Bratislava

I. - Basic information

I.1 - Surname
Boháč
I.2 - Name
Andrej
I.3 - Degrees
doc. RNDr. PhD.
I.4 - Year of birth
1964
I.5 - Name of the workplace
Comenius University in Bratislava, Faculty of Natural Sciences, Deptartment of Organic Chemistry
I.6 - Address of the workplace
Mlynská dolina, Ilkovičova 6, 841 04 Bratislava
I.7 - Position
associated professor
I.8 - E-mail address
andrej.bohac@uniba.sk
I.9 - Hyperlink to the entry of a person in the Register of university staff
https://www.portalvs.sk/regzam/detail/4178
I.10 - Name of the study field in which a person works at the university
Chemistry
I.11 - ORCID iD
https://orcid.org/0000-0002-5233-9466

II. - Higher education and further qualification growth

II.1 - First degree of higher education
II.2 - Second degree of higher education
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Natural Sciences
II.b - Year
1987
II.c - Study field and programme
Organic and Bioorganic Chemistry
II.3 - Third degree of higher education
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Natural Sciences
II.b - Year
1993
II.c - Study field and programme
Organic Chemistry
II.4 - Associate professor
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Natural Sciences
II.b - Year
2003
II.c - Study field and programme
Organic Chemistry
II.5 - Professor
II.6 - Doctor of Science (DrSc.)

III. - Current and previous employment

III.a - Occupation-position III.b - Institution III.c - Duration
associated professor Comenius University in Bratislava, Faculty of Natural Sciences since 2003 up today
assistant professor Comenius University in Bratislava, Faculty of Natural Sciences 1993 - 2003
assistant Comenius University in Bratislava, Faculty of Natural Sciences 1989 - 1993

IV. - Development of pedagogical, professional, language, digital and other skills

V. - Overview of activities within the teaching career at the university

V.1 - Overview of the profile courses taught in the current academic year according to study programmes
V.1.a - Name of the profile course V.1.b - Study programme V.1.c - Degree V.1.d - Field of study
Stereoselective synthesis Organic and Bioorganic chemistry II. Chemistry
Medicinal chemistry - drug development Organic and Bioorganic chemistry II. Chemistry
Medicinal chemistry - practical part Organic and Bioorganic chemistry II. Chemistry
Medicinal chemistry Chemistry I.
V.2 - Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year
V.2.a - Name of the study programme V.2.b - Degree V.2.c - Field of study
Chemistry I. Chemistry
Organic and Bioorganic chemistry II. Chemistry
Bioorganic chemistry III. Chemistry
V.3 - Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year
V.4 - Overview of supervised final theses
V.4.1 - Number of currently supervised theses
V.4.a - Bachelor's (first degree)
2
V.4.b - Diploma (second degree)
2
V.4.c - Dissertation (third degree)
2
V.4.2 - Number of defended theses
V.4.a - Bachelor's (first degree)
12
V.4.b - Diploma (second degree)
29
V.4.c - Dissertation (third degree)
9
V.5 - Overview of other courses taught in the current academic year according to study programmes

VI. - Overview of the research/artistic/other outputs

VI.1 - Overview of the research/artistic/other outputs and the corresponding citations
VI.1.1 - Number of the research/artistic/other outputs
VI.1.a - Overall
181
VI.1.b - Over the last six years
36
VI.1.2 - Number of the research/artistic/other outputs registered in the Web of Science or Scopus databases
VI.1.a - Overall
46
VI.1.b - Over the last six years
20
VI.1.3 - Number of citations corresponding to the research/artistic/other outputs
VI.1.a - Overall
430
VI.1.b - Over the last six years
175
VI.1.4 - Number of citations registered in the Web of Science or Scopus databases
VI.1.a - Overall
430
VI.1.b - Over the last six years
175
VI.1.5 - Number of invited lectures at the international, national level
VI.1.a - Overall
11
VI.1.b - Over the last six years
4
VI.2 - The most significant research/artistic/other outputs
1

Development of Novel Oxotriazinoindole Inhibitors of Aldose Reductase: Isosteric Sulfur/Oxygen Replacement in the Thioxotriazinoindole Cemtirestat Markedly Improved Inhibition Selectivity. Hlaváč, M., Kováčiková, L., Prnová, M.Š., Šramel, P., Addová, G., Májeková, M., Hanquet, G., Boháč, A., Štefek, M. Journal of Medicinal Chemistry 2020, 63, 369-381. (https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01747)

2

Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands. Murár, M., Dobiaš, J., Šramel, P., Addová, G., Hanquet, G., Boháč, A. European Journal of Medicinal Chemistry 2017, 126, 754-761. (https://doi.org/10.1016/j.ejmech.2016.11.003)

3

Ynamide Click chemistry in development of triazole VEGFR2 TK modulators. Vojtičková, M., Dobiaš, J., Hanquet, G., Addová, G., Cetin-Atalay, R., Yildirim, D.C., Boháč, A. European Journal of Medicinal Chemistry 2015, 103, 105-122. (https://doi.org/10.1016/j.ejmech.2015.08.012)

4

A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex – Medicinal chemistry consequences of a TKs analysis. Lintnerová, L., García-Caballero, M., Gregáň, F., Melicherčík, M., Quesada, A.R., Dobiaš, J., Lác, J., Sališová, M., Boháč, A. European Journal of Medicinal Chemistry 2014, 72, 146-159. (https://doi.org/10.1016/j.ejmech.2013.11.023)

5

Preparation and Structural Analysis of Several New α,α,α′,α′-Tetraaryl-1,3-dioxolane-4,5-dimethanols (TADDOL's) and TADDOL analogs, their evaluation as titanium ligands in the enantioselective addition of methyltitanium and diethylzinc reagents to benzaldehyde, and refinement of the mechanistic hypothesis. Ito, Y.N., Ariza, X., Beck, A.K., Boháč, A., Ganter, C., Gawley, R.E., Kühnle, F.N.M., Tuleja, J., Wang, Y.M., Seebach, D. Helvetica Chimica Acta 1994 77, 2071-2110. (https://doi.org/10.1002/hlca.19940770802)

VI.3 - The most significant research/artistic/other outputs over the last six years
1

Inhibition of Glycolysis Suppresses Cell Proliferation and Tumor Progression In Vivo: Perspectives for Chronotherapy. Horváthová, J., Moravčík, R., Matúšková, M., Šišovský, V., Boháč, A., Zeman, M. International Journal of Molecular Sciences 2021, 22, 4390. (https://doi.org/10.3390/ijms22094390)

2

Development of Novel Oxotriazinoindole Inhibitors of Aldose Reductase: Isosteric Sulfur/Oxygen Replacement in the Thioxotriazinoindole Cemtirestat Markedly Improved Inhibition Selectivity. Hlaváč, M., Kováčiková, L., Prnová, M.Š., Šramel, P., Addová, G., Májeková, M., Hanquet, G., Boháč, A., Štefek, M. Journal of Medicinal Chemistry 2020, 63, 369-381. (https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01747)

3

Switchable highly regioselective synthesis of 3,4-dihydroquinoxalin-2(1H)ones from o-phenylenediamines and aroylpyruvates. Dobiaš, J., Ondruš, M., Addova, G., Bohač, A. Beilstein Journal of Organic Chemistry 2017, 13, 1350-1360. (https://doi.org/10.3762/bjoc.13.132)

4

Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands. Murár, M., Dobiaš, J., Šramel, P., Addová, G., Hanquet, G., Boháč, A. European Journal of Medicinal Chemistry 2017, 126, 754-761. (https://doi.org/10.1016/j.ejmech.2016.11.003)

5

Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase. Kimani, S.G., Kumar, S., Davra, V., Chang, Y.-J., Kasikara, C., Geng, K., Tsou, W.-I., Wang, S., Hoque, M., Boháč, A., Lewis-Antes, A., De Lorenzo, M.S., Kotenko, S.V., Birge, R.B. Cell Communication and Signaling 2016, 14, 19. (https://dx.doi.org/10.1186%2Fs12964-016-0142-1)

VI.4 - The most significant citations corresponding to the research/artistic/other outputs
1

Journal of Medicinal Chemistry 2020, 63, 369: Novel 3,4-dihydroquinolin-2(1H)-one derivatives as dual inhibitor targeting AKR1B1/ROS for treatment of diabetic complications: Design, synthesis and biological evaluation. Han, Z., Qi, G., Zhu, J., Zhang, Y., Xu, Y., Yan, K., Zhu, C., Hao, X.(2020) Bioorganic Chemistry, 105, art. no. 104428.

Aldose reductase and protein tyrosine phosphatase 1B inhibitors as a promising therapeutic approach for diabetes mellitus. Kousaxidis, A., Petrou, A., Lavrentaki, V., Fesatidou, M., Nicolaou, I., Geronikaki, A.(2020) European Journal of Medicinal Chemistry, 207, art. no. 112742.

[4 + 2]-Annulation of Prop-2-ynylsulfonium Salts and Isatoic Anhydrides: Access to 3-Methylthio-4-quinolones. Chen, Q., Pan, Y., Yue, T., Yang, W., Liu, H., Zheng, J. (2020) Organic Letters, 22 (15), pp. 6096-6100.

Oxidative degradation of high-molar-mass hyaluronan: Effects of some indole derivatives to hyaluronan decay. Valachová, K., Mach, M., Šoltés, L. (2020) International Journal of Molecular Sciences, 21 (16), art. no. 5609, pp. 1-12.

2

European Journal of Medicinal Chemistry 2017, 126, 754: Current scenario of 1,3-oxazole derivatives for anticancer activity. Yan, X., Wen, J., Zhou, L., Fan, L., Wang, X., Xu, Z. (2020) Current Topics in Medicinal Chemistry, 20 (21), pp. 1916-1937. Cited 1 time.

Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors. El Kerdawy, A.M., Osman, A.A., Zaater, M.A. (2019) Journal of Molecular Modeling, 25 (6), art. no. 171, . Cited 9 times.

Autoregulation of the human splice factor kinase CLK1 through exon skipping and intron retention Uzor, S., Zorzou, P., Bowler, E., Porazinski, S., Wilson, I., Ladomery, M.

(2018) Gene, 670, pp. 46-54. Cited 11 times.

Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells. Bowler, E., Porazinski, S., Uzor, S., Thibault, P., Durand, M., Lapointe, E., Rouschop, K.M.A., Hancock, J., Wilson, I., Ladomery, M. (2018) BMC Cancer, 18 (1), art. no. 355, . Cited 32 times.

Preparation of oxazolines and oxazoles via a PhI(OAc)2-promoted cyclization of N-propargylamides Yi, W., Liu, Q.-Y., Fang, X.-X., Lou, S.-C., Liu, G.-Q.

(2018) Organic and Biomolecular Chemistry, 16 (38), pp. 7012-7018. Cited 16 times.

3

European Journal of Medicinal Chemistry 2015, 103, 105: Recent advance in oxazole-based medicinal chemistry. Zhang, H.-Z., Zhao, Z.-L., Zhou, C.-H.(2018) European Journal of Medicinal Chemistry, 144, pp. 444-492. Cited 115 times.

An investigation on the second-order nonlinear optical response of cationic bipyridine or phenanthroline iridium(iii) complexes bearing cyclometallated 2-phenylpyridines with a triphenylamine substituent. Hierlinger, C., Cordes, D.B., Slawin, A.M.Z., Colombo, A., Dragonetti, C., Righetto, S., Roberto, D., Jacquemin, D., Zysman-Colman, E., Guerchais, V. (2018) Dalton Transactions, 47 (25), pp. 8292-8300. Cited 13 times.

Design, synthesis and biological evaluation of novel benzimidazole amidines as potent multi-target inhibitors for the treatment of non-small cell lung cancer. Bistrović, A., Krstulović, L., Harej, A., Grbčić, P., Sedić, M., Koštrun, S., Pavelić, S.K., Bajić, M., Raić-Malić, S.(2018) European Journal of Medicinal Chemistry, 143, pp. 1616-1634. Cited 32 times.

Mechanistic applications of click chemistry for pharmaceutical drug discovery and drug delivery. Meghani, N.M., Amin, H.H., Lee, B.-J.

(2017) Drug Discovery Today, 22 (11), pp. 1604-1619. Cited 43 times.

The 1,2,3-triazole ring as a bioisostere in medicinal chemistry. Bonandi, E., Christodoulou, M.S., Fumagalli, G., Perdicchia, D., Rastelli, G., Passarella, D. (2017) Drug Discovery Today, 22 (10), pp. 1572-1581. Cited 220 times.

4

European Journal of Medicinal Chemistry 2014, 72, 146: Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation. Eissa, I.H., El-Helby, A.-G.A., Mahdy, H.A., Khalifa, M.M., Elnagar, H.A., Mehany, A.B.M., Metwaly, A.M., Elhendawy, M.A., Radwan, M.M., ElSohly, M.A., El-Adl, K.

(2020) Bioorganic Chemistry, 105, art. no. 104380, . Cited 9 times.

Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4(3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers. Mahdy, H.A., Ibrahim, M.K., Metwaly, A.M., Belal, A., Mehany, A.B.M., El-Gamal, K.M.A., El-Sharkawy, A., Elhendawy, M.A., Radwan, M.M., Elsohly, M.A., Eissa, I.H.

(2020) Bioorganic Chemistry, 94, art. no. 103422, . Cited 35 times.

Recent advance in oxazole-based medicinal chemistry. Zhang, H.-Z., Zhao, Z.-L., Zhou, C.-H. (2018) European Journal of Medicinal Chemistry, 144, pp. 444-492. Cited 115 times.

Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz, M.A., Abdel-Mohsen, H.T., El Kerdawy, A.M., Ragab, F.A.F., Ali, M.M., Abu-bakr, S.M., Girgis, A.S., El Diwani, H.I. (2017) European Journal of Medicinal Chemistry, 136, pp. 315-329. Cited 35 times.

Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs. Zhang, J., Jiang, X., Jiang, Y., Guo, M., Zhang, S., Li, J., He, J., Liu, J., Wang, J., Ouyang, L.

(2016) European Journal of Medicinal Chemistry, 108, pp. 495-504. Cited 54 times.

5

Helvetica Chimica Acta 1994 77, 2071: Quantitative Structure-Selectivity Relationships in Enantioselective Catalysis: Past, Present, and Future. Zahrt, A.F., Athavale, S.V., Denmark, S.E. (2020) Chemical Reviews, 120 (3), pp. 1620-1689. Cited 34 times.

Enhancement of the Catalytic Activity of Chiral H8-BINOL Titanium Complexes by Introduction of Sterically Demanding Groups at the 3-Position. Hayashi, Y., Yamamura, N., Kusukawa, T., Harada, T. (2016) Chemistry - A European Journal, 22 (34), pp. 12095-12105. Cited 10 times.

Catalytic Synthesis of Enantiopure Chiral Alcohols via Addition of Grignard Reagents to Carbonyl Compounds. Collados, J.F., Solaì, R., Harutyunyan, S.R., Maciá, B. (2016) ACS Catalysis, 6 (3), pp. 1952-1970. Cited 38 times.

Enantioselective titanium-promoted 1,2-additions of carbon nucleophiles to carbonyl compounds. Pellissier, H. (2015) Tetrahedron, 71 (17), pp. 2487-2524. Cited 34 times.

Trans-hydrogenation: Application to a concise and scalable synthesis of brefeldin. Fuchs, M., Fürstner, A. (2015) Angewandte Chemie - International Edition, 54 (13), pp. 3978-3982. Cited 67 times.

VI.5 - Participation in conducting (leading) the most important research projects or art projects over the last six years
1

Medicinal chemistry – an efficient development of inhibitors of selected key biological targets connected with tumor progression; 2018-2021; VEGA 1/0670/18

2

Multi-target paradigm for innovative ligand identification in the drug discovery process; 2016-2020; COST CA15135

3

Development of organic SMO tyrosine kinase modulators as drug candidates; 2016-2017; APVV-SK-FR-2015-0014

4

Syntéza a biologické testovanie počítačom navrhnutých inhibítorov VEGFR-2 kinázy, aplikácia poznatkov pre vývoj inhibítorov ovplyvňujúcich rezistenciu rakovinových kmeňových buniek; 2013-2016; VEGA 1/0634/13

5

Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells; 2012-2016; COST CM1106

VII. - Overview of organizational experience related to higher education and research/artistic/other activities

VII.a - Activity, position VII.b - Name of the institution, board VII.c - Duration
Member of the commission for PhD studies in the Pharmaceutical Chemistry study program Comenius University in Bratislava, Faculty of Pharmacy 2017-present
Coordinator for the Comenius University and member of the International network for awarding PhDs in European medicinal chemistry Paul Ehrlich European PhD Network in Medicinal Chemistry http://www.pehrlichmedchem.eu/index.php?page=network 2011-present
A chairman of the medical chemistry specialist group at the Slovak Chemical Society Slovak Chemical Society 2010-present
Member of the commission for PhD studies in the Polymer Chemistry study program at SAS The Slovak Academy of Sciences 2021-present

VIII. - Overview of international mobilities and visits oriented on education and research/artistic/other activities in the given field of study

VIII.a - Name of the institution VIII.b - Address of the institution VIII.c - Duration (indicate the duration of stay) VIII.d - Mobility scheme, employment contract, other (describe)
Swiss Federal Institute of Technology (ETH) Zurich (research group of Prof. Camille Ganter) Zurich, Switzerland 1993-1996 (27 months) Postdoctoral fellowship
University of Strasbourg (Dr. Gilles Hanquet) Strasbourg, France 2009-2011 (3 x 5 days) A series of lectures on medicinal chemistry via Erasmus program for Mgr. students from University of Strasbourg, France
University of Strasbourg (Dr. Gilles Hanquet) Strasbourg, France 2010-2021 (4 PhD joint students) Cotutelle joint PhD supervising

IX. - Other relevant facts

IX.a - If relevant, other activities related to higher education or research/artistic/other activities are mentioned

Pfize award for research in medicinal chemistry 2009 "Pfizer Research Award".

Four jointly supervised PhD students within the Cotutelle program with the University of Strasbourg, France 2010-2021.

The first introduction of electronic databases for 12 Slovak universities: ScienceDirect, Scopus, ESI, SciFinder 2005.

Introduction of new subjects Stereoselective synthesis and Medicinal chemistry at Faculty of Natural Sciences, Comenius University in Bratislava in years 1996 and 2003.

Date of last update
2024-11-12